The American Journal of Managed Care December 2010
Part D Coverage Gap and Adherence to Diabetes Medications
The coverage gap in the Medicare Part D program has a significant negative impact on adherence to diabetes medications.
Objective: To evaluate the impact of Medicare Part D coverage gap (donut hole) on adherence to diabetes medications.
Study Design: Retrospective cohort analysis based on pharmacy claims data.
Methods: The sample included 12,881 Medicare Part D beneficiaries with diabetes who entered the coverage gap in 2008. Sample patients had 3 different levels of coverage in the donut hole: no coverage, generic drug coverage only, and both generic and brand-name drug coverage. Adherence was measured by the proportion of days covered. We used a difference-in-difference model to evaluate the effect of coverage gap on adherence.
Results: In the donut hole, the average copayment for diabetes medications increased substantially for beneficiaries with no coverage and beneficiaries with generic drug coverage only, whereas the average copayment for beneficiaries with both generic and brand-name medication coverage declined slightly. Compared with beneficiaries with full coverage of both generic and brand-name drugs, beneficiaries with no coverage (odds ratio[OR] = 0.617, P <.0001, 95% confidence interval [CI] = 0.523, 0.728) and beneficiaries with generic drug coverage only (OR = 0.702, P <.0001, 95% CI = 0.604, 0.816) were significantly less likely to be adherent after entering the donut hole. The difference between having generic coverage and no coverage was not significant (P = .1586).
Conclusions: The coverage gap in the Medicare Part D program has a significant negative impact on medication adherence among beneficiaries with diabetes. Availability of brand-name drug coverage in the donut hole is critical to adherence to diabetes medications.
(Am J Manag Care. 2010;16(12):911-918)
The Medicare Part D coverage gap has a significant negative impact on adherence to diabetes medications.
- The average copayment of diabetes medications increased substantially for beneficiaries with no coverage or only generic coverage in the donut hole.
- Beneficiaries with no coverage or only generic coverage in the donut hole were significantly less likely to be adherent to diabetes medications in the donut hole.
- Offering only generic coverage in the donut hole has a limited impact on patients' adherence to diabetes medications.
The donut hole is a controversial component of the Part D design because a lack of benefit may negatively impact patients’ drug utilization and subsequent clinical outcomes. Studies have shown that beneficiaries of private drug benefit plans with annual benefit limits are more likely to discontinue their medications and have a higher rate of hospitalization compared with beneficiaries who have no benefit limits.1,2 Sun et al reported that the donut hole was associated with reductions in medications used for potentially disabling and life-threatening conditions.3 Another study by Zhang et al indicated that beneficiaries with no coverage in the donut hole decreased their use of monthly prescriptions by about 14%.4
In this study, we examine the effects of the Part D coverage gap on adherence to diabetes medications. We focused on diabetes because diabetes is a serious chronic medical condition with considerable morbidity and mortality. The prevalence rate of diabetes is high among senior citizens (23.1%), compared with 7.8% in the US population.5 In 2007, over half of the $174 billion economic cost of diabetes was attributed to people 65 years and older, and a large portion of these costs were borne by Medicare.6
Previous studies on the Part D coverage gap generally used the number of prescriptions filled as the outcome variable.3,4 It is difficult to link the number of prescriptions with important outcomes such as hospitalizations and glycosylated hemoglobin (A1C) levels to help decision making in Part D benefit design. Our research focused on adherence to diabetes medications, a critical component in the management of diabetes. Aggressive glycemic management, as measured by A1C, can reduce long-term complications7 and medical costs associ-ated with diabetes treatment.8,9 Poor adherence to diabetes medications is a major contributor to unsatisfactory glycemic control10-13 and increases the risk of adverse health events associated with diabetes.14-16 Inadequate adherence to diabetes medications in the donut hole could have serious long-term consequences for both Medicare and Medicare beneficiaries.
Data Source and Sample Selection
This study is a retrospective cohort analysis based on prescription drug claims data provided by MedImpact Healthcare Systems, Inc, a national pharmacy benefit management company. Compared with the national data, Part D beneficiaries in MedImpact had the same sex distribution but were less likely to be under age 65 years (Table 1).
The sample in this research included patients over age 65 years who were continuously enrolled in a Medicare Part D plan from January 1, 2007, to December 31, 2008, and had at least 2 diabetes medication claims in each year. This study required patients to use diabetes medications in 2007 to ensure that all patients had used diabetes medications prior to the study period, January 1, 2008, to December 31, 2008. Utilization data in 2007 were used to acquire comorbidity information. Patients who received low-income subsidies for their premium and copayment were excluded from the sample because of their unique benefit structure.
A total of 35,426 patients were identified using these criteria. Among these patients, 37.10% reached the donut hole in 2008 but did not reach the catastrophic limit, 13.38% reached both the donut hole and the catastrophic limit, 49.44% never reached the donut hole, and the remaining 0.09% reached the catastrophic limit directly without entering the donut hole. We selected only patients who had reached the donut hole but not the catastrophic limit for this research.3,4 The final sample contained 12,881 patients from more than 30 different health plans.
Coverage in Donut Hole
Part D patients can have different types of Part D plans, including the defined standard benefit (DSB) plan, the actuarially equivalent (AE) plan, the basic alternative (BA) plan, and the enhanced alternative (EA) plan. The AE and BA plans are equivalent to DSB plans in value and do not provide coverage in the donut hole. The EA plans charge a supplemental premium and provide supplemental benefits. Many EA plans cover either generic drugs only or both generic and brand-name drugs as supplemental benefits.
In our analysis, we designated 3 groups of Part D beneficiaries based on their coverage in the donut hole. The first group consisted of beneficiaries with no donut hole coverage (“no coverage” group). This group included beneficiaries with DSB, AE, or BA plans and beneficiaries with EA plans that did not offer coverage in the donut hole. The second group comprised beneficiaries with only generic drug coverage in the donut hole (“generic coverage only” group) from EA plans. The third group included beneficiaries with both generic and brand-name drug coverage in the donut hole (“full coverage” group) from EA plans. All Part D plans identified in this research had $2510 and $5726.25 for the start and end of the donut hole.
The outcome measure of interest was adherence to diabetes medications. In this analysis, adherence to diabetes medications was measured by the proportion of days covered (PDC), calculated as the number of days covered by at least 1 diabetes medication in a certain period of time, divided by the number of days in that period. To calculate a PDC, each day in that period was evaluated as covered or as not covered by a medication based on fill date and days of supply. If a new claim for the same diabetes medication occurred before the end date of the last claim, the starting date of the new claim was pushed forward to the end date of the last claim. We calculated 2 PDCs for each patient: one for the period before reaching the coverage gap (pregap PDC) and the other for the period after reaching the coverage gap (postgap PDC). Patients with a PDC of 80% or more were classified as adherent.10,14-18 In addition to a dichotomous adherence variable, we used continuous PDC as the outcome variable to test the robustness of the results.
Control variables include age, sex, whether patient used insulin in the prior 12 months, geographic region (Northeast, South, Midwest, and West), and comorbidities in the prior 12 months. Comorbidity indicators were constructed based on the RxRisk model of comorbid conditions.19 A series of dummy variables for each major comorbid condition were
created for the analysis.
We used a difference-in-difference regression analysis to measure the effect of coverage gap on adherence to diabetes medications. The difference-in-difference method used patients with full coverage in the donut hole as the control group because these patients experienced little copayment change in the donut hole. The experimental group consisted of patients in the other 2 groups (no coverage and generic coverage only), who experienced substantial copayment increases in the donut hole.
Two challenges in measuring the effect of the donut hole are that (1) patients may self-select different levels of coverage and (2) they may have different propensities for being adherent to diabetes medications. The difference-in-difference method addresses this issue by having repeated observations for the same patient in both the pregap period and postgap periods. A group fixed effect was used to control for the permanent differences across different groups, and a time fixed effect was used to control for the secular trend within the study period. The true donut hole effect is the difference in adherence to diabetes medications between the control and the experimental groups in the donut hole, adjusting for the difference between the control and the experimental groups before entering the donut hole.
Table 2 presents the patients’ characteristics. The average age for the entire sample was 74.97 years, and 48.06% of patients in the sample were male. A typical patient spent around 104 days in the donut hole. The vast majority of patients in the sample lived in the Midwest (82.85%). The most significant comorbidities were hypertension (87.41%), hyperlipidemia (81.54%), and heart disease/hypertension (69.47%).
About a third (33.47%) of patients used insulin in the prior 12 months. Among patients who used insulin in 2007, the percentages using short-acting, intermediate-acting, long-acting, and mixed insulin were 32.27%, 25.68%, 55.56%, and 27.67%, respectively. These categories are not mutually exclusive because a patient could have used more than 1 type of insulin in 2007.
In the sample, 19.63% of the 12,881 beneficiaries had no coverage in the donut hole, 20.08% of beneficiaries were covered for generic drugs only, and 54.28% of beneficiaries had full coverage. Patients with no coverage in the donut hole were slightly older (75.40 years) than patients with generic coverage only (74.85 years) and patients with full coverage (74.87 years). Patients with generic coverage only had the longest stay in the donut hole (107.96 days), and patients with no coverage in the donut hole spent the shortest time in the donut hole (99.91 days); patients with full coverage fell in between (103.54 days).
Table 3 shows the adherence rates and average copayments for patients in the sample. The adherence rate before reaching the donut hole for the no-coverage group was 0.82, which was close to the adherence rates of 0.81 for the group with generic coverage only and 0.85 for the group with full coverage. After reaching the donut hole, the adherence rate of patients with no coverage dropped 8 percentage points to 0.74. Similarly, the adherence rate of patients with generic coverage dropped 6 percentage points to 0.75. In contrast, patients with full coverage maintained their adherence rate at 0.85 in the donut hole.
The coverage gap had a substantial impact on copayment. The average copayment (per 30 days of supply, the same thereafter) of all diabetes medications before reaching the donut hole was $18.63 for patients with no coverage, $18.63 for patients with generic coverage only, and $16.48 for patients with full coverage. After reaching the donut hole, the average copayment increased to $69.20 (a 271% increase) for the group with no coverage and to $67.18 (a 261% increase) for the group with generic coverage only. Partially because of the increased use of 90 days of supply, the average copayment for patients with full drug coverage actually decreased slightly to $14.33 after reaching the donut hole.